Swedish skin cancer diagnostic start-up AI Medical Technology has completed the latest stage in its ongoing strategic transformation, appointing two renowned executives to its board.
Stockholm, Sweden, May 14, 2024 – AI Medical Technology, developer of Dermalyser, a smartphone-based tool capable of diagnosing skin cancer with higher sensitivity and specificity than trained dermatologists, has appointed two key new members to its board of directors.
The first is Emil Billbäck. As the CEO of the highly successful company BoneSupport, Billbäck has led the company’s rapid commercialization of its pioneering Orthobiologics platform, rendering a share price appreciation of over 800% over the past five years.
Speaking on Billbäck’s appointment, Christoffer Ekström, AI Medical Technology’s CEO, says: “Having Billbäck join us is a huge affirmation that the hard work we are putting into saving patients’ lives with Dermalyser is not only providing a societal benefit, but also addressing a strong commercial potential. Billbäck will be a mentor to my team and guide my personal transformation from an R&D CEO into a commercial one.”
“BoneSupport is a highly innovative company transforming an outdated standard of care in the field of orthopedic surgery. We at AI Medical Technology intend to follow a similar path and aspire for Dermalyser to improve and replace current melanoma diagnosis workflows.”
The second new member of AI Medical Technology’s team is Peter Löwendahl. As the holder of over 15 Data Protection Officer and Person Responsible for Regulatory Compliance roles, Löwendahl’s work at AI Medical Technology will be focused on regulatory clearance for Dermalyser, as well as securing reimbursement.
“Both clearance and reimbursement are key for our company,” says Ekström. “We have an incredible technology with a truly unique value proposition and fantastic user feedback. Our next step is ensuring that we are fully compliant with robust reimbursement model in place ahead of a successful market launch.”
For more information, please contact:
Christoffer Ekström, CEO AI Medical Technology
Email: christoffer@aimedtech.com
Cell phone: +46704 02 71 01
Melanoma skin cancer According to Cancer Today, one person dies of skin cancer every four minutes. In 2020, the incidence of new melanoma cases was over 320,000 worldwide, with this figure expected to reach almost 500,000 by 2040. Further statistics show that as many as 99% of the cases are curable if they are diagnosed and treated early enough, underscoring the importance of continuous self-examination and visiting your doctor in the case of a suspected skin lesion. Hence, early and accurate diagnosis is vital for saving more lives https://gco.iarc.fr/today/home
About Dermalyser Dermalyser is a mobile application powered by artificial intelligence (AI) that can provide diagnostic decision support for medical professionals in clinical settings. Dermalyser enables fast and direct diagnostic decision support with high accuracy when diagnosing skin cancer such as melanoma of the skin. The application is used with a dermatoscope mounted in front of the smartphone camera. The Medical professional takes an image of the patients’ skin lesion and, within a few seconds, receives a diagnosis from the AI in return. In a recent study1, Demalyser demonstrated formidable diagnostic performance: 95% sensitivity and 86% specificity, outperforming both primary care physicians and specialist dermatologists. By using Dermalyser, healthcare systems can not only spot more cancers at earlier stages, which will save lives, but also improve efficiency and lower costs, since fewer patients will need to undergo unnecessary biopsy procedures.
1Panagiotis Papachristou, et.al. (2024), Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial, British Journal of Dermatology, 00:1–9, https://doi.org/10.1093/bjd/ljae021
About AI Medical Technology AI Medical Technology is a company operating in the interdisciplinary fields of data science, software development, and medicine. The company is dedicated to developing AI-powered diagnostic solutions that enable frontline healthcare practitioners to make easier, faster and more reliable diagnoses for their patients. Following its most recent funding round, a bridge financing worth $1.15m in April 2024, the team is now focused on bringing the first product, Dermalyser, a clinically validated decision support tool for diagnosing skin cancer, through clinical trials and to the market. For more information see www.aimedtech.com and https://www.linkedin.com/company/aimedicaltechnolog